05.27.15
Charlottesville, Va.-based Rivanna Medical, a medical device company developing a platform of ultrasound-based technology, has named John A. Williams as president and CEO. He replaces Will Mauldin, Ph.D., a co-founder of Rivanna who remains as chairman and chief technology officer of the company.
Rivanna currently is commercializing the Accuro platform, a proprietary imaging product that is U.S. Food and Drug Administration (FDA) 510(k)-cleared for spinal anesthesia guidance and a variety of additional imaging applications, such as diagnostic imaging of the cardiac and abdominal anatomies.
Williams has successfully built and sold publicly and privately held healthcare companies. He is known as a strong strategic and analytical thinker with a track record of developing new technologies to accelerate growth, according to Rivanna. His turnaround experience, coupled with his ability to create and execute a long-term vision, consistently has enhanced shareholder value. Williams has raised more than $80 million for the companies he has led.
“Rivanna’s co-founders have done a phenomenal job of building the company and developing the Accuro platform with relatively minimal funding to date,” Williams said in a news release. “There are numerous clinical applications for Accuro. Our initial commercial application of the platform is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia.”
“We are extremely pleased to welcome John Williams to Rivanna,” said Mauldin. “Certainly, his track record of raising funds for emerging companies bodes well for Rivanna, as we step up our efforts to commercialize the first FDA-cleared product from the Accuro platform—designed to facilitate spinal anesthesia guidance with real-time 3-D navigation of the lumbar spine.”
Rivanna currently is commercializing the Accuro platform, a proprietary imaging product that is U.S. Food and Drug Administration (FDA) 510(k)-cleared for spinal anesthesia guidance and a variety of additional imaging applications, such as diagnostic imaging of the cardiac and abdominal anatomies.
Williams has successfully built and sold publicly and privately held healthcare companies. He is known as a strong strategic and analytical thinker with a track record of developing new technologies to accelerate growth, according to Rivanna. His turnaround experience, coupled with his ability to create and execute a long-term vision, consistently has enhanced shareholder value. Williams has raised more than $80 million for the companies he has led.
“Rivanna’s co-founders have done a phenomenal job of building the company and developing the Accuro platform with relatively minimal funding to date,” Williams said in a news release. “There are numerous clinical applications for Accuro. Our initial commercial application of the platform is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia.”
“We are extremely pleased to welcome John Williams to Rivanna,” said Mauldin. “Certainly, his track record of raising funds for emerging companies bodes well for Rivanna, as we step up our efforts to commercialize the first FDA-cleared product from the Accuro platform—designed to facilitate spinal anesthesia guidance with real-time 3-D navigation of the lumbar spine.”